ALCON, AMGEN TO COLLABORATE ON OPHTHALMOLOGIC DRUGS

U.S.-based drugmakers Alcon and Amgen have entered into a multitarget collaboration to jointly research, develop, and commercialize therapeutics for the treatment of eye diseases, the companies announced.

Under the terms of the agreement, Amgen will provide existing and future molecules that have been or are identified to have potential utility in eye disease. Alcon will lead clinical development and commercialization activities for the molecules.

"This agreement is an important step for Alcon that reflects the continued success of our strategic initiative to increase our access to the building blocks of future ophthalmic medicines," said Cary Rayment, president and CEO of Alcon.